Dean Rudge
Deputy Editor
Dean has built up a wealth of knowledge on the global generics and biosimilar medicines industries since joining Generics Bulletin in 2013. He specializes in commercial and legal issues, writing in-depth analyses of corporate strategy and getting under the skin of patent infringement proceedings and other litigation. He attends investor and regulatory meetings with business leaders, favoring the investor days with their focus on corporate strategy. In his spare time, Dean enjoys visiting museums and playing five-a-side football.
Latest From Dean Rudge
Formycon’s US Eylea Biosimilar Is Third In Six Weeks – But Timing Still Uncertain
A third US biosimilar to Regeneron’s Eylea has won approval. However, enthusiasm is muted at this stage as biosimilar sponsors, including latest recipient Formycon, continue to battle against court-issued blockades.
What’s Next? Five Things To Look Out For In July
Generics Bulletin previews the most noteworthy and anticipated events for July 2024.
Apotex Is Latest To Accuse Amarin Of ‘Freezing Out’ Vascepa Competition
Apotex is the latest generics manufacturer that feels Amarin has engineered a “systematic effort to ensure that no other company could manufacture the generic version of its product,” Vascepa, by locking up API supply, with the Canadian firm taking legal action in a bid to bring the originator’s alleged conduct to a halt.
Coherus All But Checks Out Of Biosimilars With Meitheal Adalimumab Deal
Meitheal Pharmaceuticals can begin preparations for a seminal moment, the firm’s first marketed US biosimilar, as it snapped up rights to Humira rival Yusimry from Coherus BioSciences.
‘Totality, Not Piecemeal’: US Federal Circuit Revives Hikma Vascepa Skinny-Label Suit
Reading Hikma’s press releases and other public documents made it “at least plausible” that a physician would look to prescribe Hikma’s generic Vascepa product for any of its indications, including the highly-valued, patent-protected cardiovascular indication, the US Federal Circuit has decided, reopening a lawsuit against the generics firm.
AAM Knocked Back In Illinois Price-Gouging Lawsuit
Off-patent industry association the US Association for Accessible Medicines will have to reevaluate after a US district court in Illinois found that it had no standing to secure injunctive relief against a state price-control bill.